BACKGROUND: Clostridium difficile infection (CDI) is a leading cause of infectious complications in allogeneic hematopoietic cell transplant recipients (alloHCT). We sought to evaluate whether prophylactic oral vancomycin reduces the incidence of CDI in alloHCT recipients. METHODS: We conducted a retrospective cohort study to examine the effectiveness of CDI prophylaxis with oral vancomycin, as compared to no prophylaxis, in 145 consecutive adult alloHCT recipients at the University of Pennsylvania between April 2015 and November 2016. Patients received oral vancomycin 125 mg twice daily, starting on admission and continuing until discharge. The primary outcome of interest was the association between oral vancomycin prophylaxis and CDI diagnosis. Secondary outcomes included graft-versus-host disease (GVHD) and relapse. RESULTS: There were no cases of CDI in patients that received prophylaxis (0/90, 0%), whereas 11/55 (20%) patients who did not receive prophylaxis developed CDI (P < .001). Oral vancomycin prophylaxis was not associated with a higher risk of acute, grades 2-4 GVHD (subhazard ratio [sHR] 1.59; 95% confidence interval [CI] 0.88-2.89; P = .12), acute, grades 3-4 GVHD (sHR 0.65; 95% CI 0.25-1.66; P = .36), or acute, grades 2-4 gastrointestinal GVHD (sHR 1.95; 95% CI 0.93-4.07; P = .08) at day 180 post-transplant. No associations between oral vancomycin and relapse or survival were observed. CONCLUSIONS: Prophylaxis with oral vancomycin is highly effective in preventing CDI in alloHCT recipients without increasing the risk of graft-versus-host disease or disease relapse. Further evaluation via a prospective study is warranted.
BACKGROUND:Clostridium difficileinfection (CDI) is a leading cause of infectious complications in allogeneic hematopoietic cell transplant recipients (alloHCT). We sought to evaluate whether prophylactic oral vancomycin reduces the incidence of CDI in alloHCT recipients. METHODS: We conducted a retrospective cohort study to examine the effectiveness of CDI prophylaxis with oral vancomycin, as compared to no prophylaxis, in 145 consecutive adult alloHCT recipients at the University of Pennsylvania between April 2015 and November 2016. Patients received oral vancomycin 125 mg twice daily, starting on admission and continuing until discharge. The primary outcome of interest was the association between oral vancomycin prophylaxis and CDI diagnosis. Secondary outcomes included graft-versus-host disease (GVHD) and relapse. RESULTS: There were no cases of CDI in patients that received prophylaxis (0/90, 0%), whereas 11/55 (20%) patients who did not receive prophylaxis developed CDI (P < .001). Oral vancomycin prophylaxis was not associated with a higher risk of acute, grades 2-4 GVHD (subhazard ratio [sHR] 1.59; 95% confidence interval [CI] 0.88-2.89; P = .12), acute, grades 3-4 GVHD (sHR 0.65; 95% CI 0.25-1.66; P = .36), or acute, grades 2-4 gastrointestinal GVHD (sHR 1.95; 95% CI 0.93-4.07; P = .08) at day 180 post-transplant. No associations between oral vancomycin and relapse or survival were observed. CONCLUSIONS: Prophylaxis with oral vancomycin is highly effective in preventing CDI in alloHCT recipients without increasing the risk of graft-versus-host disease or disease relapse. Further evaluation via a prospective study is warranted.
Authors: Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh Journal: Biol Blood Marrow Transplant Date: 2009-10 Impact factor: 5.742
Authors: J M Vossen; P J Heidt; H van den Berg; E J Gerritsen; J Hermans; L J Dooren Journal: Eur J Clin Microbiol Infect Dis Date: 1990-01 Impact factor: 3.267
Authors: Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2005-12 Impact factor: 5.742
Authors: Anne Vrieze; Carolien Out; Susana Fuentes; Lisanne Jonker; Isaie Reuling; Ruud S Kootte; Els van Nood; Frits Holleman; Max Knaapen; Johannes A Romijn; Maarten R Soeters; Ellen E Blaak; Geesje M Dallinga-Thie; Dorien Reijnders; Mariëtte T Ackermans; Mireille J Serlie; Filip K Knop; Jenst J Holst; Claude van der Ley; Ido P Kema; Erwin G Zoetendal; Willem M de Vos; Joost B L Hoekstra; Erik S Stroes; Albert K Groen; Max Nieuwdorp Journal: J Hepatol Date: 2013-12-06 Impact factor: 25.083
Authors: Carolyn D Alonso; Suzanne B Treadway; David B Hanna; Carol Ann Huff; Dionissios Neofytos; Karen C Carroll; Kieren A Marr Journal: Clin Infect Dis Date: 2012-03-12 Impact factor: 9.079
Authors: Erik R Dubberke; Kimberlay A Reske; Anand Srivastava; Justin Sadhu; Robert Gatti; Rebecca M Young; Lauren C Rakes; Brian Dieckgraefe; John DiPersio; Victoria J Fraser Journal: Clin Transplant Date: 2009-07-13 Impact factor: 2.863
Authors: D W Beelen; E Haralambie; H Brandt; G Linzenmeier; K D Müller; K Quabeck; H G Sayer; U Graeven; H K Mahmoud; U W Schaefer Journal: Blood Date: 1992-11-15 Impact factor: 22.113
Authors: Robert R Jenq; Carles Ubeda; Ying Taur; Clarissa C Menezes; Raya Khanin; Jarrod A Dudakov; Chen Liu; Mallory L West; Natalie V Singer; Michele J Equinda; Asia Gobourne; Lauren Lipuma; Lauren F Young; Odette M Smith; Arnab Ghosh; Alan M Hanash; Jenna D Goldberg; Kazutoshi Aoyama; Bruce R Blazar; Eric G Pamer; Marcel R M van den Brink Journal: J Exp Med Date: 2012-04-30 Impact factor: 14.307
Authors: Sarah W Baron; Belinda E Ostrowsky; Priya Nori; David Y Drory; Michael H Levi; Wendy A Szymczak; Michael L Rinke; William N Southern Journal: Infect Control Hosp Epidemiol Date: 2020-02 Impact factor: 3.254
Authors: Matthew Ziegler; Jennifer H Han; Daniel Landsburg; David Pegues; Emily Reesey; Cheryl Gilmar; Theresa Gorman; Kristen Bink; Amy Moore; Brendan J Kelly Journal: Open Forum Infect Dis Date: 2019-05-31 Impact factor: 3.835